Abingdon, United Kingdom

Colin Lindley

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cellcentric Limited. Active years: 2022.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Colin Lindley: Innovator in Cancer Treatment

Introduction

Colin Lindley is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on creating modulators that can potentially improve therapeutic outcomes for various types of cancers.

Latest Patents

Colin Lindley holds a patent for a process aimed at preparing modulators of p300 and/or CBP. This process involves several steps, including treating specific compounds to generate an intermediate compound and ultimately recovering a compound that shows promise in modulating p300/CBP activity. The compound he has developed has potential utility in treating several cancers, including prostate cancer, haematological cancers, bladder cancer, and lung cancer. He has 1 patent to his name.

Career Highlights

Colin Lindley is currently associated with Cellcentric Limited, where he continues to work on groundbreaking research in the field of cancer therapeutics. His expertise and innovative approach have positioned him as a valuable asset in the company.

Collaborations

Colin collaborates with talented individuals such as Jonathan Trevorrow and James Vaughan Morey. Their combined efforts contribute to advancing research and development in cancer treatment.

Conclusion

Colin Lindley's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. His contributions through patents and collaborations highlight the importance of research in developing effective therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…